Fierce Biotech March 21, 2023
2022 was defined by aggressive rate hikes from the Federal Reserve, which correlated with a downturn for publicly listed biotechs. (Elena Boltunova/iStock/Getty Images Plus)
$100 million for Rapport Therapeutics. $112 million for Noema Pharma. $108 million for Bicara Therapeutics. The megaround has come roaring back in the past few weeks, but is biotech really healing?
Not quite, say executives from venture capital and biotech incubator firms. Series A rounds are an easy sell at the moment, according to Leaps By Bayer Head Jürgen Eckhardt, M.D., although fewer of them overall are getting done and the ones that are, are smaller. What’s continuing to hamper biotech is the series Bs, Cs and crossover rounds that set up an...
Today's Sponsors
Today's Sponsor